At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients
The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2/3 study for cutaneous squamous cell carcinoma
Read MoreThe Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in NYSE: LYV shares. Investors in Live Nation Entertainment, Inc. (NYSE: LYV) shares should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
Read MoreThe Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in NASDAQ: XRAY shares. Investors in NASDAQ: XRAY shares should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
Read More
